GW & Wade’s Charles River Laboratories CRL Stock Holding History

GW & Wade’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,558	Closed	-$389K	–	356
2020 Q4	$389K	Buy	+1,558	New	+$371K	0.02%	218

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

GW & Wade's CRL Position: Q1 2021 in Review

GW & Wade sold out of Charles River Laboratories (CRL) in Q1 2021, closing a stake of 1,558 shares — an estimated $389K sold.

GW & Wade first reported a position in CRL in Q4 2020 and held it in 1 quarter. The position peaked at $389K in Q4 2020. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2021.

GW & Wade reported no remaining Charles River Laboratories position as of Q1 2021 after selling out during the quarter.
GW & Wade sold 1,558 Charles River Laboratories shares in Q1 2021, an estimated $389K.
GW & Wade first reported a position in Charles River Laboratories in Q4 2020 and held it in 1 quarter.
GW & Wade's Charles River Laboratories position peaked at $389K in Q4 2020.
561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2021.

Based on GW & Wade's 13F filing for Q1 2021, filed 5 May 2021.